Pilot Studies Testing the Use of Oral Amitriptyline in Reducing Localized Burn Injury-induced Microvesicle Particle Release

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorWright State University

About this trial

The purpose of this study is to determine the amount of substances contained in skin known as microvesicle particles (MVP). The hypothesis to be tested in this study is that treatment with a single dose of 75mg of amitriptyline will block the MVP released from the skin from a very small localized burn injury.

Eligibility criteria

Qualifiers

Adult Males and Females age 18 - 60

All skin types on Fitzpatrick Scale (Type I-VI)

Able to comprehend procedures and risks

Willing to participate and understand the informed consent document

Disqualifiers

Subjects should be otherwise healthy and not have any significant medical issues that could interfere with the study, in particular any heart arrythmias and not be on any prescription medications that could react with amitriptyline.

History of abnormal scarring (i.e., keloids) or poor wound healing.

No over the counter non-steroidal anti-inflammatory agents (aspirin, acetaminophen) or antioxidant vitamins (vitamin C) in past 14 days.

Currently taking known photosensitizers, anti-inflammatories, other tricyclic antidepressants, or systemic agents known to be aSMase inhibitors

Trial design

Treatments tested in this trial

  • Amitriptyline
  • Placebo

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators